Enfusion, Inc. (NYSE:ENFN) Given Average Rating of "Reduce" by Brokerages

Enfusion, Inc. (NYSE:ENFN - Get Free Report) has earned a consensus rating of "Reduce" from the six research firms that are currently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $10.00.

Separately, Stifel Nicolaus increased their price objective on Enfusion from $11.00 to $13.00 and gave the stock a "buy" rating in a research report on Wednesday.

Enfusion Stock Down 2.5 %

NYSE:ENFN traded down $0.28 during trading hours on Wednesday, reaching $10.75. 785,928 shares of the company's stock were exchanged, compared to its average volume of 387,476. Enfusion has a 1-year low of $7.52 and a 1-year high of $11.38. The company has a 50-day moving average of $9.61 and a 200 day moving average of $8.97. The firm has a market capitalization of $1.38 billion, a price-to-earnings ratio of 268.82, a P/E/G ratio of 3.98 and a beta of 0.97.

Insider Buying and Selling

In other Enfusion news, COO Neal Pawar sold 21,801 shares of Enfusion stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $10.03, for a total transaction of $218,664.03. Following the completion of the transaction, the chief operating officer now owns 1,143,544 shares in the company, valued at approximately $11,469,746.32. The trade was a 1.87 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 36.44% of the stock is owned by insiders.

Institutional Trading of Enfusion

Several institutional investors and hedge funds have recently made changes to their positions in the stock. RiverPark Advisors LLC purchased a new stake in Enfusion in the 2nd quarter worth approximately $68,000. Arizona State Retirement System purchased a new position in shares of Enfusion during the 2nd quarter worth $86,000. Harbor Capital Advisors Inc. boosted its holdings in shares of Enfusion by 12.4% during the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company's stock worth $113,000 after purchasing an additional 1,315 shares during the last quarter. Belvedere Trading LLC purchased a new stake in shares of Enfusion in the third quarter valued at $114,000. Finally, Paloma Partners Management Co acquired a new position in Enfusion in the third quarter valued at $157,000. 81.05% of the stock is currently owned by hedge funds and other institutional investors.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.